TD Asset Management
KYMR icon

TD Asset Management’s Kymera Therapeutics KYMR Stock Holding History

TD Asset Management’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$31.3M Sell
272,900
-14,200
-5% -$1.22M 0.03% 409
2026
Q1 		$23.9M Buy
287,100
+65,922
+30% +$5.22M 0.02% 478
2025
Q4 		$17.2M Buy
221,178
+11,930
+6% +$806K 0.01% 539
2025
Q3 		$11.8M Sell
209,248
-25,722
-11% -$1.16M 0.01% 610
2025
Q2 		$10.3M Buy
234,970
+32,878
+16% +$1.13M 0.01% 632
2025
Q1 		$5.53M Sell
202,092
-26,468
-12% -$965K 0.01% 769
2024
Q4 		$9.19M Buy
228,560
+21,666
+10% +$979K 0.01% 667
2024
Q3 		$10.1M Sell
206,894
-11,910
-5% -$526K 0.01% 644
2024
Q2 		$6.53M Hold
218,804
– – 0.01% 700
2024
Q1 		$8.8M Buy
218,804
+32,322
+17% +$1.16M 0.01% 651
2023
Q4 		$4.75M Buy
186,482
+2,400
+1% +$42.9K ﹤0.01% 778
2023
Q3 		$2.56M Buy
184,082
+84,167
+84% +$1.69M ﹤0.01% 889
2023
Q2 		$2.3M Buy
99,915
+5,900
+6% +$169K ﹤0.01% 932
2023
Q1 		$2.79M Buy
94,015
+14,500
+18% +$468K ﹤0.01% 895
2022
Q4 		$1.98M Buy
79,515
+900
+1% +$24K ﹤0.01% 991
2022
Q3 		$1.74M Buy
78,615
+1,939
+3% +$51.1K ﹤0.01% 1047
2022
Q2 		$1.51M Sell
76,676
-6,786
-8% -$158K ﹤0.01% 1085
2022
Q1 		$3.53M Sell
83,462
-4,858
-6% -$205K ﹤0.01% 910
2021
Q4 		$5.61M Buy
88,320
+20,355
+30% +$1.19M ﹤0.01% 834
2021
Q3 		$3.99M Buy
67,965
+3,300
+5% +$191K ﹤0.01% 878
2021
Q2 		$3.89M Buy
64,665
+38,066
+143% +$1.65M ﹤0.01% 898
2021
Q1 		$1.03M Buy
26,599
+3,598
+16% +$217K ﹤0.01% 1255
2020
Q4 		$1.43M Buy
23,001
+800
+4% +$39K ﹤0.01% 1106
2020
Q3 		$717K Buy
+22,201
New +$678K ﹤0.01% 1155

Other funds holding KYMR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
MC
Merck & Co Kenilworth, New Jersey $526M AUM 175.27% 1-Year Est. Return

TD Asset Management's KYMR Position: Q2 2026 in Review

TD Asset Management reduced its Kymera Therapeutics (KYMR) stake by 4.9% in Q2 2026, selling an estimated $1.22M and leaving 272,900 shares worth $31.3M. The position accounts for 0.03% of the portfolio, ranked #409.

TD Asset Management first reported a position in KYMR in Q3 2020 and has held it in 24 quarters since. 185 funds tracked by Wall St. Rank hold KYMR as of Q2 2026.

  • TD Asset Management held 272,900 shares of Kymera Therapeutics worth $31.3M as of Q2 2026.
  • TD Asset Management sold 14,200 Kymera Therapeutics shares in Q2 2026, an estimated $1.22M.
  • Kymera Therapeutics made up 0.03% of TD Asset Management's portfolio in Q2 2026, its #409 holding.
  • TD Asset Management first reported a position in Kymera Therapeutics in Q3 2020 and has held it in 24 quarters since.
  • 185 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q2 2026.

Based on TD Asset Management's 13F filing for Q2 2026, filed 4 Aug 2026.